- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vericel Corp Ord (VCEL)
Vericel Corp Ord stock price live, this page displays NASDAQ VCEL stock exchange data. View the VCEL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vericel Corp Ord real time stock price chart below.
What Is the Vericel Corp Ord Stock Price Today?
The Vericel Corp Ord stock price today is 44.07.
What Is the Stock Symbol for Vericel Corp Ord?
The stock symbol for Vericel Corp Ord is "VCEL."
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the NASDAQ stock exchange.
Is Vericel Corp Ord a Good Stock to Buy?
Determining whether Vericel Corp Ord—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCEL quote. (ISIN: US92346J1088)
What Is the Vericel Corp Ord Stock Price Today?
The Vericel Corp Ord stock price today is 44.07.
What Is the Stock Symbol for Vericel Corp Ord?
The stock symbol for Vericel Corp Ord is "VCEL."
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the NASDAQ stock exchange.
Is Vericel Corp Ord a Good Stock to Buy?
Determining whether Vericel Corp Ord—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VCEL quote. (ISIN: US92346J1088)
43.83
-0.71(-1.59%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.65
44.55
52 wk Range
28.95
49.32
VCEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
43.6544.55
52 wk Range
28.9549.32
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VCEL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
60.57
Upside
+38.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Form 144 Vericel Corp For: 3 August- Investing.com
Aastrom Bioscienc receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 144 Vericel Corp For: 3 August
- Investing.com
- Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aastrom Bioscienc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 60.57
(+38.20% Upside)
Vericel Corp Ord SWOT Analysis
MACI Arthro Triumph | Vericel's FDA approval for MACI Arthro expands its cartilage repair market, positioning it as the only arthroscopic biologic solution for knee defects up to 4cm2 |
Market Expansion Strategy | Delve into Vericel's plan to grow its surgeon base from 5,000 to 7,000, targeting high-volume arthroscopic specialists to drive MACI Arthro adoption |
Revenue Potential | Explore how MACI Arthro could significantly boost Vericel's revenues by penetrating the 2-4cm² condyle defect market, potentially doubling total MACI sales |
Competitive Edge | Learn about Vericel's strengthened position in the $3 billion cartilage repair market, with analysts setting a price target of $57.00 for August 2024 |
Vericel Corp Ord Earnings Call Summary for Q2/2026
- Vericel Q2 revenue hit $77.5M (+22% YoY), beating estimates by $4.75M; EPS of $0.04 vs. expected loss of $0.03, marking first Q2 profit in company history.
- MACI cartilage repair revenue reached record $65.5M (+23% YoY), fifth consecutive quarter of 20%+ growth; burn care revenue rose 22% to $12M driven by Epicel and NexoBrid.
- Company raised FY 2026 revenue guidance to $330M-$340M from $320M-$330M; expects gross margin of ~75% and adjusted EBITDA margin of ~27% for full year.
- Board approved first-ever $200M share repurchase program; company generated $14.3M free cash flow in Q2, fourth straight quarter above $12M with cash rising to $227M.
- U.K. marketing authorization for MACI submitted in Q2 with approval expected by end-2026; company targets $500M revenue by decade-end with EBITDA margins in high 30s by 2029.
Last Updated: 2026-07-30, 09:34 a/m
Read Full TranscriptEarnings
Latest Release
Jul 30, 2026
EPS / Forecast
0.04 / -0.03
Revenue / Forecast
77.45M / 72.7M
Compare VCEL to Peers and Sector
Metrics to compare | VCEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCELPeersSector | |
|---|---|---|---|---|
P/E Ratio | 92.3x | −2.2x | −0.4x | |
PEG Ratio | 0.37 | −0.05 | 0.00 | |
Price/Book | 6.0x | 1.5x | 2.6x | |
Price / LTM Sales | 7.3x | 4.1x | 3.1x | |
Upside (Analyst Target) | 32.5% | 82.2% | 48.4% | |
Fair Value Upside | Unlock | 15.6% | 6.5% | Unlock |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Vericel Corp Ord (VCEL) Stock Price Today?
The Vericel Corp Ord stock price today is 43.83 USD.
What Stock Exchange Does Vericel Corp Ord Trade On?
Vericel Corp Ord is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Vericel Corp Ord?
The stock symbol for Vericel Corp Ord is "VCEL."
What Is the Vericel Corp Ord Market Cap?
As of today, Vericel Corp Ord market cap is 2.25B USD.
What Is Vericel Corp Ord's Earnings Per Share (TTM)?
The Vericel Corp Ord EPS (TTM) is 0.47.
When Is the Next Vericel Corp Ord Earnings Date?
Vericel Corp Ord will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is VCEL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Vericel Corp Ord Stock Split?
Vericel Corp Ord has split 2 times.
How Many Employees Does Vericel Corp Ord Have?
Vericel Corp Ord has 398 employees.
What is the current trading status of Vericel Corp Ord (VCEL)?
As of Aug 14, 2026, Vericel Corp Ord (VCEL) is trading at a price of 43.83 USD, with a previous close of 44.54 USD. The stock has fluctuated within a day range of 43.65 USD to 44.55 USD, while its 52-week range spans from 28.95 USD to 49.32 USD.
What Is Vericel Corp Ord (VCEL) Price Target According to Analysts?
The average 12-month price target for Vericel Corp Ord is 60.57 USD, with a high estimate of 72 USD and a low estimate of 55 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +38.20% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.